ProCE Banner Activity

SOPHIA: Phase III Trial of Margetuximab + CT vs Trastuzumab + CT in Patients With HER2+ Metastatic Breast Cancer After Standard Anti-HER2 Therapies

Slideset Download
Conference Coverage
Margetuximab + CT resulted in improved PFS and ORR vs trastuzumab + CT in patients with HER2+ MBC after ≥ 2 previous lines of anti-HER2 therapy.

Released: June 06, 2019

Expiration: June 04, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro